Jeffrey Sosman
-
Investigators find clues to melanoma treatment resistance
Nearly half of all patients with malignant melanoma, the most deadly form of skin cancer, have a mutation in the BRAF gene found in their tumors. Mutations in the BRAF gene turn on a cancer growth switch known as the MAP kinase pathway. Read MoreOct 29, 2015
-
Bradfords’ strong support bolsters melanoma research
When something attacks you, you want to attack it back. That’s how Lillian “Tooty” Bradford views her late husband James “Jimmy” Bradford Jr.’s decision to make an initial gift to fund melanoma research at Vanderbilt-Ingram Cancer Center (VICC). Read MoreSep 25, 2014
-
VICC researchers in spotlight at national cancer conference
New Vanderbilt research suggests patients with advanced melanoma — the most deadly form of skin cancer — could safely benefit from a combination of immunotherapy and targeted therapies aimed at specific gene mutations. Read MoreJun 19, 2014
-
VU study identifies new gene fusions in melanoma
Cancer researchers, led by investigators at Vanderbilt-Ingram Cancer Center, have identified two novel gene fusions in melanoma that may be responsive to existing cancer therapies. Melanoma is the most deadly form of skin cancer. Read MoreDec 19, 2013
-
Sosman to lead national melanoma research team
Jeffrey Sosman, M.D., professor of Medicine and leader of the Vanderbilt Melanoma Program, will head one of two teams of researchers at prominent national institutions investigating acral melanoma, a skin cancer that typically forms on the hands, soles of the feet or under the fingernails. Read MoreDec 12, 2013
-
Sosman named one of ‘hottest’ researchers in U.S.
Jeffrey Sosman, M.D., professor of Medicine, Ingram Chair for Cancer Research and director of the Vanderbilt Melanoma Program, was named one of the Hottest Scientific Researchers of the last year by Thomas Reuters Science Watch. Read MoreSep 26, 2013
-
2013 Academic Enterprise Faculty Awards
The 2013 Vanderbilt University Medical Center Academic Enterprise Faculty Awards, which were presented during Wednesday’s Spring Faculty meeting, included awards for Excellence in Teaching and Outstanding Contributions to Research. Award recipients were nominated by their faculty colleagues and chosen by the Academic Enterprise Faculty Awards Selection Committee. Read MoreMay 23, 2013
-
Foundation lauds graduate student’s melanoma research
Katherine Hutchinson, a third-year graduate student in Cancer Biology at Vanderbilt University, has won a $10,000 Research Scholar Award from the Joanna M. Nicolay Melanoma Foundation. Read MoreMar 28, 2013
-
Combined drug therapy may delay melanoma progression
Combination therapy with two drugs delayed the development of treatment resistance in patients with metastatic melanoma that expresses a specific mutation in the BRAF gene. Read MoreOct 25, 2012
-
Stand Up to Cancer TV broadcast airs Sept. 7
Stand Up To Cancer (SU2C), the nonprofit organization that helps fund various Vanderbilt-Ingram Cancer Center (VICC) investigators, returns to prime time television for its third broadcast Friday, Sept. 7, at 7 p.m. The hourlong show featuring Hollywood celebrities, recording artists and sports figures will include special performances… Read MoreAug 30, 2012
-
Study finds mutation in melanoma sensitive to drug
An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to a specific drug therapy, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation. Read MoreJul 26, 2012
-
New cancer drug shows promise in early testing
An experimental drug that activates T-cells and promotes an immune response to fight tumors has shown promising early results in patients with kidney cancer, melanoma and non-small cell lung cancer. Leora Horn, M.D. Vanderbilt-Ingram Cancer Center investigators Leora Horn, M.D., Jeffrey Sosman, M.D., and researchers from several other cancer… Read MoreJul 12, 2012
-
Risk of secondary tumors from melanoma drug studied
A new study offers clues on why melanoma patients who are treated with oral drugs inhibiting the BRAF gene are at increased risk for developing secondary skin cancers. Read MoreMar 23, 2012
-
New melanoma drug nearly doubles survival in majority of patients
Investigators from Vanderbilt-Ingram Cancer Center and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival. Read MoreFeb 23, 2012
-
Investigators seek clues to resistance to melanoma drug
Investigators at Vanderbilt-Ingram Cancer Center and several other centers may be one step closer to finding out why some melanoma patients relapse after treatment with a promising new drug. Read MoreJan 26, 2012
-
Sosman named to ‘Dream Team’ of cancer investigators
Jeffrey Sosman, M.D., professor of Medicine at Vanderbilt-Ingram Cancer Center (VICC), has been named to a melanoma research Dream Team of cancer investigators supported by Stand Up To Cancer (SU2C) and the Melanoma Research Alliance (MRA). Sosman is among the Dream Team’s principal investigators who will work closely with the… Read MoreJan 5, 2012
-
Kudos
Caudill (Vanderbilt) Devin Bender, a support specialist in the emergency department; Melinda Caudill, a medical technologist in the Virology Laboratory; and Katie Gentry, a child life specialist, each have received the Credo Award, given to staff and faculty who exemplify Vanderbilt University Medical Center’s standards for service and all-around… Read MoreJan 1, 2012
-
Jeffrey Sosman named to melanoma research ‘Dream Team’
Jeffrey Sosman (Vanderbilt) Jeffrey Sosman, professor of medicine at Vanderbilt-Ingram Cancer Center (VICC), has been named to a melanoma research Dream Team of cancer investigators supported by Stand Up To Cancer (SU2C) and the Melanoma Research Alliance. Sosman is among the Dream Team’s principal investigators who… Read MoreDec 15, 2011